USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent Licensed to Regulus
- Sterne, Kessler, Goldstein & Fox
Sterne Kessler client Santaris Pharma A/S announces that the U.S. Patent and Trademark Office has granted its request for an inter partes reexamination of a patent licensed to Regulus Therapeutics Inc.
U.S. patent number 7,838,504 claims right to a method of reducing viral genome amount in a cell infected with Hepatitis C. The Order issued by the USPTO states that Santaris' request "establishes a reasonable likelihood that Santaris will prevail" with respect to the claims under reexamination. Additionally, the USPTO issued an Office Action that rejected the reexamined claim.
The Santaris Pharma A/S patent reexamination team is led by Eric K. Steffe of Sterne, Kessler, Goldstein & Fox, P.L.L.C.